Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Columbia University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02362373CT.gov Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Epilepsy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Levonorgestrel (this asset) | Columbia University | Approved | B · 59 |
| Eslicarbazepine Acetate | Bial - Portela C S.A. | P4 | BBB |
| Lamotrigine | Assiut University | P4 | BBB |
| Neurotop | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Lacosamide | Second Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Topiramate | Université de Sherbrooke | P4 | BBB |
| Levetiracetam | Beijing Tiantan Hospital | P4 | BBB |
| Valproic Acid | Sanofi | P4 | BBB |
| Midazolam | Haseki Training and Research Hospital | P4 | BBB |
+42 more in the Epilepsy cohort
Other indications for Levonorgestrel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | P4 | BB · 68 |
| Obesity Disorder | — | P4 | BB · 65 |
| Major Depressive Disorder | — | P4 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Levonorgestrel in Epilepsy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/levonorgestrel-epilepsy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →